RxDoctor Payments Data

William Bennett

Interventional Cardiology · Slidell, LANPI 1023288792

Payments from drug & device makers

$5,996in general payments, 2019–2025

Across 65 payments — averaging $92.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Johnson & Johnson$2K
  • Penumbra, Inc.$343
  • Janssen Scientific Affairs, LLC$306
  • Abbott$250
  • Bard Peripheral Vascular, Inc.$248
  • plus $689 from 12 others

What the payments were for

  • Consulting fees$1,35023%
  • Travel & lodging$1,87731%
  • Food & beverage$2,75646%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,996 in reported general payments places this provider in the 30th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$79,403
Medicare patients
531
Services billed
1,447

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban589$448,188
Repatha SureclickEvolocumab205$123,336
XareltoRivaroxaban83$84,054
EntrestoSacubitril/Valsartan52$42,427
Repatha SyringeEvolocumab72$41,492
Praluent PenAlirocumab74$36,774
NexlizetBempedoic Acid/Ezetimibe32$26,413
BrilintaTicagrelor24$20,745
NexletolBempedoic Acid23$15,478
FarxigaDapagliflozin Propanediol15$8,822
Bumetanide500$8,635
Cilostazol184$4,514
Atorvastatin Calcium486$4,096
Rosuvastatin Calcium205$2,084
Ezetimibe120$1,935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,816$84,05483 claims
NovartisEntresto$66$42,42752 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Slidell

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →